Press Releases & News

Inato's Liz Beatty shares her thoughts on CVS' recent exit from clinical research and the implications for other retailers entering the space.

Inato provided Insider with the pitch deck it used to raise $20 million in Series A-2 funding.

Inato recently raised $20 million in Series A2 funding for its two-way tech platform which brings clinical trial exposure to community-based providers.

After a recent FDA rule required drug makers to open up trials to underrepresented populations, startups like Inato are working to close the gap.

Inato CEO Kourosh Davarpanah told Endpoints News that with the $20 million in hand, it will pursue improvements to its diversity offerings, its focus on oncology and data collection.

French clinical trial company Inato plans to use money from its latest fundraising round of $20 million to expand its global reach, develop new innovations and attract top talent.

Inato, the leading technology platform enabling access to inclusive clinical trials, today announced the close of $20 million in Series A2 funding from existing and new investors.

Liz Beatty, alongside other industry leaders, breaks down the collaboration and trust required between pharma sponsors, research sites large and small, tech solutions, and patients to make representative trials the status quo.

A look at the ramifications of undiversified clinical trials and ways that pharma can increase representation, featuring Inato's Liz Beatty.

While the healthcare industry has seen massive transformation since the onset of the pandemic, clinical trial operations, perhaps more quietly, has been a hotbed of business activity with fast-growing digital health companies like Inato.

Industry leaders, including Inato's Liz Beatty, describe how they are navigating the key issues of 2023 with a focus on what the industry needs to do to meet the high bar of patient expectations, and what companies can do to adopt a more consumer-centric approach to patient care and engagement.

PharmaNewsIntelligence interviewed Kourosh Davarpanah, CEO and Co-founder of Inato, and Teresa L. Tocher, Director of Clinical Research at Clinical Trials Management Services, LLC, who provided some insight into the current, traditional clinical trial landscape and how clinical trial sites are connected with pharmaceutical companies to offer their patients access to care.

By leveraging the Inato platform, research sites can reuse data from one trial to another.

Today, Inato announced its latest platform enhancements. The company also grew global community site adoption of the Inato platform by more than 120% year-over-year (YOY).

Inato CEO Kourosh Davarpanah shared the company's growth over 2022 and explains how their platform empowers community-based investigators to bring the right trials to their patients.

Inato hosts two discussions around challenges in accessing patients and innovative approaches to overcoming those barriers and partnering with community-based sites at the Clinical Operations Strategy Meeting on May 18 in Cambridge, Massachusetts

In an interview with Authority Magazine for their series on "Technology Making An Important Positive Social Impact" Inato CEO, Kourosh Davarpanah, shares the motivation behind starting Inato and the positive impact our technology can have on society.

Inato CSO, Liz Beatty, describes the detrimental effect of underrepresenting minority communities in clinical trials.

CSO, Liz Beatty, describes how the lack of diversity across clinical trials harms trial efficacy, data, and costs in op-ed.

The lack of diversity in clinical trials is staggering. Liz Beatty, who has spent nearly two decades as Director of Clinical Trials at Bristol-Myers Squibb, is changing that as Inato’s Chief Strategic Officer.

Beatty brings decades of experience in leadership and clinical trial management

Liz Beatty from Inato discusses how patient experience can be enhanced when the clinical trial team shares a background with the subjects.

Inato broadens clinical trial access by offering pharmaceutical companies direct access to community-based research sites and the patients they serve

Driven by COVID’s disparate effect on certain ethnicities, the pandemic exacerbated the issue of certain patient populations being unable to access suitable trials. Proventa spoke to Liz Beatty, Chief Strategy Officer at Inato, about how they believe this issue can be rectified. 

The Inato Marketplace is Reinventing the Collaboration Model Between Clinical Trial Sponsors and Sites

"The lack of diversity in clinical trials is a disturbing, ethical problem that’s persisted for decades," said Liz Beatty in an article this week on Applied Clinical Trials Magazine where she discusses that it is time to stop talking the talk and start walking the walk when it comes to clinical trial diversity.

Clinical Research News published an article last week on some of the top trends to watch out for in clinical trials in 2021.

Experts from a variety of research and drug development organizations share their thoughts on highlights from 2020, and predict what 2021 might hold.

Inato CEO, Kourosh Davarpanah, discusses the clinical trial landscape and why the future of clinical trials will require a focus on the long tail.

Inato Announces the Participation of Over 300 Clinical Trial Research Sites in its Global Marketplace

A leader from the clinical research technology firm talks about the importance of a diverse patient population and ways to hit the target.

Inato's Liz Beatty pens an op-ed in Xconomy on the pressing need for clinical trial diversity.

To overcome sponsor-related challenges and work to successfully secure more trials, there are tactical steps CROs can take.

Inato Joins SCRS as a Global Impact Partner

By connecting supply with demand and eventually facilitating a financial transaction, marketplaces provide an online platform for supply and demand to efficiently find one another and transact seamlessly.

Inato raises $14 million series A round to “unlock the potential of the many unengaged research sites.”

Inato Raises $14 Million in Series A Funding from Obvious Ventures, Cathay Innovation, Serena and Fly Ventures

Inato announced a $14 million Series A round led by Obvious Ventures and Cathay Innovation, and joined by Serena and Fly Ventures.

Inato Appoints Pharmaceutical Industry Veteran Liz Beatty as Chief Strategy Officer